Igenica is pursuing discovery and development of its pipeline independently and with industry collaborators to address the critical needs of oncology patients. We are focused on the development of innovative immunotherapies, functional antibodies directed to the tumor, and antibody-drug conjugates for the treatment of cancer. All of Igenica’s product candidates were discovered using our proprietary product engine.
Igenica is developing IGN523 for the treatment of multiple hematologic and solid tumors. IGN523 is a humanized monoclonal antibody that binds to CD98. Expression of CD98 has been shown to be upregulated in a variety of hematologic malignancies, including AML, and in several types of solid tumors, particularly squamous cell carcinomas. IGN523 is in a Phase 1 clinical trial in patients with relapsed or refractory acute myeloid leukemia (AML). The trial is designed to assess the safety, pharmacokinetics, and clinical activity of IGN523.
IGN523 works through multiple mechanisms of action, including antibody-dependent cell-mediated cytotoxicity (ADCC), inhibition of CD98 function, and induction of apoptosis. CD98 is a heterodimeric cell surface protein that is implicated in the pathogenesis of many hematological and solid malignancies. Its elevated expression is correlated with poor prognosis and patient outcome. Previous studies have demonstrated that CD98 functions both in integrin signaling and amino acid transport processes, which support the proliferation, anchorage-independence, invasion, and metastasis of tumor cells.
IGN786 is specific for a particularly novel target called SAIL or (c15orf54). Discovered using Igenica’s sTAg protoemics technology, CLL-01 has not been studied or described in humans previously. Given the expression profile of this target, IGN786 has the potential to be an exquisitely specific targeted therapy for multiple cancer indications with high unmet medical need, including follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), multiple myeloma, and pancreatic cancer. Igenica is developing IGN786 as an antibody-drug conjugate using Igenica's proprietary ADC technology. Igenica has filed patent applications with claims protecting multiple unique aspects of this novel therapeutic agent.
IGN381 is an innovative approach to immunotherapy targeting an immune checkpoint target called VISTA or cl0orf54 that plays a complimentary role in the tumor micro-environment to other known immune checkpoints. Igenica has an active antibody program under development and has humanized a lead candidate. We believe this program is well positioned to compliment existing immunotherapy approaches. Igenica has filed patent applications on these antibodies and other novel aspects of this program.